Skip to content
naulon
Not checkedNot checked for notices yet.

Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient

M. Criel, A. Vandermeulen, K. Vanhove and 4 more

Current Problems in Cancer: Case Reports · 2020

doi:10.1016/j.cpccr.2020.100035 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Malignant Pleural Mesothelioma (MPM) is a highly invasive tumor that is linked to previous asbestos exposure. Combined multimodality treatment, i.e. induction chemotherapy followed by surgery, is standard of care in highly selected patients with localized disease. Platinum-doublet chemotherapy is the first choice for inoperable or advanced disease. Currently, there are no good recommendations for second-line treatment due to the lack of a clear survival benefit. We report the case of an MPM patient that showed a remarkable response through the combination of immunotherapy and radiotherapy. This case illustrates that despite failure of single-agent checkpoint inhibition, the combination of immunotherapy and radiotherapy has the potential to overcome checkpoint-inhibitor resistance in MPM.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.